Abstract Nebivolol is a highly selective b 1 -adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition to cardioselectivity mediated via b 1 receptor blockade, nebivolol induces nitric oxide-mediated vasodilation by stimulating endothelial nitric oxide synthase via b 3 agonism. This vasodilatory mechanism is distinct from those of other vasodilatory b-blockers (carvedilol, labetalol), which are mediated via a-adrenergic receptor blockade. Nebivolol is approved for the treatment of hypertension in the US, and for hypertension and heart failure in Europe. While b-blockers are not recommended within the current US guidelines as first-line therapy for treatment of essential hypertension, nebivolol has shown comparable efficacy to currently recommended therapies in lowering peripheral blood pressure in adults with hypertension with a very low rate of side effects. Nebivolol also has beneficial effects on central blood pressure compared with other b-blockers. Clinical data also suggest that nebivolol may be useful in patients who have experienced erectile dysfunction while on other b-blockers. Here we review the pharmacological profile of nebivolol, the clinical evidence supporting its use in hypertension as monotherapy, add-on, and combination therapy, and the data demonstrating its positive effects on heart failure and endothelial dysfunction.
Introduction
Nebivolol (Bystolic Ò ) is a third-generation, long-acting and highly selective b 1 adrenoreceptor antagonist that also exhibits nitric oxide (NO)-mediated vasodilatory effects via b 3 receptor agonism and reduces oxidative stress [1] . The b 3 receptor agonism differentiates nebivolol from traditional, non-vasodilatory b 1 -blockers, such as atenolol, as well as from the vasodilatory b-blockers carvedilol and labetalol, which act via a 1 adrenergic antagonism [1] . Nebivolol does not exhibit intrinsic sympathomimetic activity or membrane-stabilizing activity. In the US, nebivolol is indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents, and has been evaluated for the treatment of chronic heart failure.
In this article, we discuss the unique pharmacology of nebivolol and review its clinical efficacy and safety.
Literature Search Methodology
Discussion of safety and efficacy was limited to hypertension, heart failure (HF), and erectile dysfunction. Literature searches, conducted in the period OctoberDecember 2014, were performed using the PubMed database (without the limit in regard to date), looking for terms 'nebivolol', 'hypertension', 'blood pressure', 'heart failure', and 'erectile dysfunction' in titles and abstracts, and restricting the results to studies in humans and nonreview articles in English language. Both authors examined the resulting lists of abstracts and excluded those that did not fit the scope of the article.
Pharmacology of Nebivolol
b-Blockers are a heterogeneous class of compounds that have evolved from first-generation, nonselective agents (e.g., propranolol) to second-generation, cardioselective b 1 -blockers (e.g., atenolol, bisoprolol, metoprolol) to third-generation compounds that combine b-blockade with vasodilatory properties (e.g., carvedilol, labetalol, nebivolol) [2] . Nebivolol is highly b 1 -selective at doses B10 mg per day, with approximately 320-fold greater affinity for b 1 than b 2 receptors in the cells of human myocardium [3] . While the vasodilatory properties of carvedilol and labetalol are mediated by a-adrenergic receptor blockade [4] , nebivolol exerts these effects by increasing endothelium-derived NO via stimulatory effect on endothelial nitric oxide synthase (NOS), mediated through b 3 agonism [5] [6] [7] [8] .
The distinct pharmacologic profile of nebivolol is associated with a number of hemodynamically relevant effects: (1) b 1 -blockade, which decreases resting and exercise heart rate, myocardial contractility, and both systolic and diastolic blood pressure; (2) NO-mediated vasodilation that results in a decrease in peripheral vascular resistance, an increase in stroke volume and ejection fraction, and maintenance of cardiac output [1] ; (3) vasodilation and reduced oxidative stress that are thought to contribute to the neutral and possibly beneficial effects of nebivolol on glucose and lipid metabolism [9, 10] ; and (4) reduced platelet volume and aggregation [11, 12] . These attributes suggest a potentially broad usefulness for nebivolol in the treatment of hypertension and chronic heart failure.
Clinical Pharmacokinetics of Nebivolol
The absolute bioavailability of nebivolol is unknown. The drug is 98 % protein bound, primarily to albumin, and reaches a peak concentration after 1.5-4 h. Nebivolol is metabolized in the liver, mainly via direct glucuronidation and secondarily through cytochrome P450 2D6 (CYP450 2D6). The active metabolites, hydroxyl and glucuronides, contribute to the b-blocking effect of nebivolol. As with other drugs metabolized via CYP450 2D6, genetic differences can impact metabolism, elimination half-life, excretion, and clinical and adverse effects of nebivolol. It should, however, be noted that data suggests that in CYP450 2D6 poor metabolizers, no dose adjustment is needed as the clinical effect and safety profiles are similar to that of extensive metabolizers [13] .
The elimination half-life of nebivolol is typically 12 h, but is prolonged to 19 h in those who are poor metabolizers. Excretion of nebivolol is 35 % through urine and 44 % via feces in average metabolizers; patients who are poor metabolizers excrete 67 % of the drug in urine and 13 % in feces [13] .
Endothelial and Hemodynamic Effects
Endothelial dysfunction caused by oxidative stress has been implicated in the development of hypertension [14] . A number of studies have demonstrated favorable endothelial effects of nebivolol versus non-vasodilatory b 1 -selective blockers (atenolol, metoprolol). For example, nebivolol was shown to be superior to atenolol in improving small artery distensibility index [15] , parameters of oxidative stress [16] , flow-mediated dilation of the brachial artery [17, 18] , and plasma concentration of asymmetric dimethyl arginine (ADMA) [18] , an endogenous inhibitor of NO production that has been associated with cardiovascular risk [19] . Compared with metoprolol, nebivolol reduces plasma ADMA levels and the augmentation index (AIx) [20] , a surrogate measure of arterial stiffness that is also associated with cardiovascular risk [21] . However, the AIx benefits compared with metoprolol may not extend to individuals with hypertension and diabetes mellitus who are receiving maximal tolerated doses of renin-angiotensinaldosterone system (RAAS) blockers [22] . Of note, a 12-month randomized trial that compared the effects of nebivolol and metoprolol on a number of hemodynamic and biochemical parameters found no difference in AIx and ADMA levels between the two groups, but demonstrated that only nebivolol had a beneficial effect on oxidative stress [23] and significantly reduced central systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), and left ventricular wall thickness [24] . Whether these positive effects translate to improvement of clinical outcomes remains to be seen.
Despite the absence of data from large outcome studies with nebivolol, the vascular effects and hemodynamic profile suggest potential advantages of nebivolol compared with non-vasodilating b 1-selective and nonselective b-blockers in the treatment of hypertension. Central hemodynamic effects are important to highlight, because they are independent predictors of cardiovascular morbidity and mortality [25, 26] and because they may be a key reason why traditional b-blockers (e.g., atenolol) have been associated with smaller reductions in cardiovascular morbidity and mortality than other antihypertensive classes (e.g., calcium channel blockers) [27] .
For example, studies have shown that, relative to atenolol and metoprolol succinate, nebivolol improves central hemodynamics and reduces arterial stiffness in patients with hypertension, regardless of similar reductions in peripheral DBP and SBP [24, [28] [29] [30] . In one study, 40 individuals with untreated essential hypertension were randomized to atenolol 50 mg/day or nebivolol 5 mg/day for 4 weeks; treatment with nebivolol reduced aortic PP to a significantly greater extent than atenolol (-16 vs -11 mmHg; p = 0.04) [29] . Though both compounds significantly reduced aortic pulse wave velocity (PWV) from baseline, only nebivolol treatment was associated with a significant reduction from baseline in AIx (from 35 to 28 %; p \ 0.05). Furthermore, PP amplification, a hemodynamic indicator inversely associated with large artery stiffness and peripheral arterial resistance [27] , was significantly increased with nebivolol treatment and significantly decreased with atenolol. Similar results were obtained in a randomized, cross-over study of 16 patients with untreated isolated systolic hypertension (ISH) [28] who received atenolol 50 mg/day, nebivolol 5 mg/day, and placebo for 5 weeks each. The significant reductions in aortic PWV compared with placebo were similar between nebivolol and atenolol, but nebivolol treatment was associated with a smaller increase in AIx compared with atenolol (6 vs 10 %; p = 0.04). The aortic PP after treatment with nebivolol was similar to that of placebo, but was significantly lower compared with treatment with atenolol (50 vs 54 mmHg; p = 0.02) [28] .
A few more recent publications also provided evidence of improvement in central hemodynamics with nebivolol. For example, in a trial that randomized 45 patients with stage I hypertension to nebivolol (10 mg/day), lifestyle modifications, or the combination of nebivolol and lifestyle modifications for 12 weeks, the b-stiffness index, a bloodpressure-independent measure of arterial stiffness, decreased (p \ 0.01), and arterial compliance increased (p = 0.02) [31] . Another trial randomized 138 patients with mild to moderate hypertension to atenolol (50-100 mg/day) or nebivolol (5 mg/day) for 10 weeks, with hydrochlorothiazide 25 mg/day added on if necessary to control blood pressure. After adjusting for heart rate, the mean between-group difference in AIx was 2.4 % (p = 0.041), with nebivolol increasing AIx to a lesser extent than atenolol [30] . Lastly, in a trial that compared nebivolol (5 mg/day) with metoprolol succinate (50-100 mg/day) in patients with mild to moderate hypertension, nebivolol reduced mean central PP from baseline significantly more than metoprolol (-6.2 vs -0.3 mmHg; p = 0.01), with no difference from baseline with either agent in PP amplification, PWV, or AIx [24] . The differential effects on aortic PP between nebivolol and atenolol or metoprolol succinate observed in these studies are similar in magnitude to those between the amlodipineand atenolol-based therapies reported in the Conduit Artery Function Evaluation (CAFE) study [32] , a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; N = 19,257), which demonstrated a greater reduction in major cardiovascular events and mortality with the amlodipine-based than atenolol-based regimen, despite a similar decrease in brachial blood pressure [33] . The question of whether the more favorable effects of nebivolol on central aortic pressure versus those of non-vasodilating b-blockers translate into improved clinical outcomes would have to be tested in large primary or secondary prevention trials.
As mentioned previously, nebivolol is a b 1 -selective blocker that exerts a vasodilatory effect through stimulation of endothelial NOS [1] . The contribution of vasodilation to the overall antihypertensive effect of nebivolol was recently assessed in a small, double-blind, placebo-controlled cross-over study of 20 patients with autonomic failure [34] , who are devoid of adrenergic input in blood pressure control and are therefore characterized by an impaired baroreceptor function, as manifested through orthostatic hypotension and supine hypertension. In that trial, nebivolol (5 mg) but not metoprolol (50 mg) lowered night-time SBP (p = 0.036) and DBP (p \ 0.001) versus placebo, effects that were driven by the subgroup of individuals who also responded to sildenafil (25 mg) [34] . This reduction in blood pressure that is independent of b 1 -antagonism is consistent with the hypothesis that NO-mediated vasodilation contributes significantly to an overall antihypertensive effect of nebivolol.
While nebivolol's NO-mediated vasodilatory effects may be favorable, there is concern about the development of nitrate tolerance and the adverse endothelial effects that are associated with the continuous long-term use of organic nitrates [1] . In a small study of 16 healthy patients who were taking either nebivolol 5 mg or placebo for 8 days, forearm blood flow was measured before and after 5 min of intravenous nitroglycerin administration (4 lg/kg body weight/min). The blood flow increase in those receiving nebivolol (96 %) was significantly greater than the increase observed in those receiving placebo (54 %; p \ 0.05) [35] . This reduction in nitrate tolerance following nebivolol treatment remains to be confirmed in larger trials.
Nebivolol for the Treatment of Hypertension
Nebivolol at doses of 1.25-40 mg/day has been evaluated for the treatment of hypertension, both as monotherapy and in combination with other classes of antihypertensive agents (Table 1) . It is provided in tablets of 2.5, 5, 10, and 20 mg; for most patients, it is recommended to start with a dose of 5 mg daily, which can be titrated up to 40 mg/day at 2-week intervals [13] . A lower initial dose of 2.5 mg/day is recommended in patients with moderate hepatic and/or severe renal impairment. However, nebivolol should be avoided in patients with severe hepatic impairment and has not been studied in patients who are receiving dialysis [13] . While nebivolol monotherapy is approved in the US for lowering blood pressure, recent treatment guidelines from the American Society of Hypertension and the International Society of Hypertension [36] , as well as the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [37] , do not recommend first-line use of b-blockers in patients with essential hypertension. The rationale provided by JNC 8 is based on results from several randomized controlled trials in which either b-blockers performed similarly to the recommended therapies of thiazide-type diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin II receptor blockers (ARBs) or firm conclusions could not be made from the evidence [37] . Additionally, the results of one trial comparing a b-blocker (atenolol) and an ARB (losartan) showed that despite similar reductions in blood pressure, losartan prevented more cardiovascular morbidity and mortality than atenolol [38] . One meta-analysis and one systematic review, which were not included as supporting evidence for recommendations in JNC 8, have also shown no benefit of b-blockers compared with other antihypertensives in reducing cardiovascular morbidity and mortality, along with an increased risk of stroke [39, 40] . It has been noted that atenolol, a non-vasodilating b 1 -selective blocker, was used in the large majority of studies included in these meta-analyses, and the finding therefore may not be generalizable to third-generation, vasodilatory b-blockers such as carvedilol and nebivolol [41] .
Monotherapy Data

Pivotal Trials
The approval of nebivolol for the treatment of hypertension in the US was based upon evidence of its efficacy in three large, randomized, placebo-controlled dose-ranging studies in adults with hypertension [42] [43] [44] . In each study, patients were randomized to 12 weeks of double-blind treatment with various fixed doses of nebivolol or placebo following a 4-to 6-week single-blind, placebo washout period. The primary efficacy parameter was change from baseline in mean trough DBP; secondary parameters included change from baseline in mean trough SBP and a response rate at endpoint, defined as the proportion of patients with mean trough DBP \90 mmHg or an absolute reduction of C10 mmHg from baseline. In total, over 2000 patients were included, with one trial consisting of black participants only [43] . Results from each study consistently showed significant reductions in DBP with nebivolol doses ranging from 5 to 40 mg daily and reductions in SBP at higher daily doses (10-20 mg), as well as significantly higher response rates compared with placebo. A dose-response effect in terms of both SBP and DBP reduction was observed [42] [43] [44] .
Pooled Analyses
Post-hoc, pooled analyses from the three pivotal trials (N = 2016) discussed above were conducted to assess efficacy, safety, and tolerability with a greater statistical power [45] , as well as to explore the effects of nebivolol on patients by age [46] and body mass index (BMI) [47] . The pooled data demonstrated a significant effect of nebivolol over placebo on both DBP and SBP for all clinically recommended dosages (5-40 mg/day), and showed that nebivolol is generally safe and well tolerated [45] . The discontinuation rate due to adverse events (AEs) among nebivolol-treated patients (all dosages) was low (2.6 %) and comparable to that observed with placebo (2.0 %). The most common AEs in patients receiving nebivolol were headache (7.1 vs 5.9 % for placebo), fatigue (3.6 vs 1.5 %), and dizziness (2.9 vs 2.0 %).
Similar efficacy results were reported in a pooled analysis of 205 placebo-treated patients and 1380 patients treated with nebivolol dosages of 5, 10, or 20 mg/day, stratified by age (22-46, 47-53, 54-62 , and 63-84 years) [46] . In all age groups, each nebivolol dose significantly reduced DBP compared with placebo. All dosages of nebivolol in all age groups significantly lowered SBP versus placebo, with the exception of the oldest age group, in whom a significant effect was observed only with the 20 mg/day dosage [46] . A pooled analysis examining the 
-9.5 ± 1. [47] . Response rates at the end of treatment were significantly higher for all nebivolol dosages C2.5 mg/day in the non-obese group and C5 mg/day in the moderately obese group [47] . [48] . A trial conducted in self-identified Hispanics also demonstrated a significant decrease in DBP (change from baseline: -11.1 mmHg vs -7.3 mmHg; p \ 0.0001) and SBP (-14.1 mmHg vs -9.3 mmHg; p = 0.001) with nebivolol treatment, compared with placebo [49] . Finally, in the pivotal trial conducted in African-Americans, nebivolol significantly reduced both DBP at all doses C5 mg (5 mg, p = 0.004; 10, 20, and 40 mg, p \ 0.001) and SBP at all doses C10 mg (10 mg, p = 0.044; 20 mg, p = 0.005; 40 mg, p = 0.002) compared with placebo [43] .
Monotherapy Trials in Special Populations
Placebo-controlled trials of nebivolol monotherapy in specific patient populations include one conducted in younger patients (age range, 18-54 years; mean age, 45.3 years) with stage 1 or stage 2 hypertension in which nebivolol significantly reduced DBP (change from baseline: -11.8 mmHg vs -5.5 mmHg; p \ 0.001) and SBP (change form baseline: -13.7 mmHg vs -5.5 mmHg; p \ 0.001), compared with placebo
Nebivolol Versus Active Comparators
The antihypertensive efficacy of nebivolol monotherapy has been established in controlled trials with active comparators [24, [28] [29] [30] [50] [51] [52] [53] [54] . Two such studies compared nebivolol to the non-vasodilatory b 1 -selective blocker, atenolol, in adults with mild to moderate hypertension [50, 54] . In one study, 364 patients were randomized to nebivolol 5 mg/day, atenolol 50 mg/day, or placebo. Results indicated that both active compounds were statistically superior to placebo and comparable to each other in terms of reducing DBP and SBP [54] . In another study, 205 patients were randomized to nebivolol 5 mg/day or atenolol 100 mg/day, and the diuretic hydrochlorothiazide (HCTZ; 12.5 mg/day) was added to either treatment arm after 8 weeks if BP control was not achieved (approximately 20 % in each group required concomitant HCTZ treatment) [50] . Comparable to the trial discussed previously, treatment with nebivolol and atenolol resulted in similarly significant antihypertensive effects versus baseline, with reductions in DBP and SBP of -14.8 mmHg and -19.1 mmHg for nebivolol, and -14.6 mmHg and 0.001, all) . Addition of HCTZ resulted in an equal additional antihypertensive effect in both groups versus monotherapy (p \ 0.03) [50] .
Nebivolol was also tested in active-controlled trials with ACEIs, ARBs, and CCBs [51] [52] [53] 55] . In an 8-week, crossover, double-blind, randomized trial, significant and comparable reductions in DBP and SBP were observed with nebivolol (2.5-10 mg/day) and lisinopril (10-40 mg/day) [51] . In a 12-week, randomized, doubleblind trial, nebivolol (5 mg/day) significantly reduced DBP (-12 mmHg at 6 and 12 weeks) versus losartan (50 mg/day; -8 mmHg and -10 mmHg after 6 and 12 weeks, respectively) [53] , with significantly more losartan-treated patients requiring add-on HCTZ (12.5 mg/day) treatment to achieve BP control. Similar significant reductions in SBP from baseline were observed with nebivolol and losartan. In two separate trials, the efficacy of nebivolol was comparable in lowering SBP and DBP with the dihydropyridine CCBs, sustained-release nifedipine, and amlodipine, with the exception that more patients required the addition of HCTZ to achieve BP control in the trial with amlodipine [52, 55] .
Add-On and Combination Trials
Many patients with hypertension require more than a single antihypertensive agent to achieve target blood pressure [56, 57] . The efficacy of nebivolol monotherapy and in combination with other antihypertensive therapies was studied in a double-blind 9-month extension study [58] in which 845 patients from one of three 12-week studies [42] [43] [44] [58] . In a separate trial in patients with uncontrolled stage 1 or stage 2 hypertension, 12 weeks of treatment with nebivolol (5, 10 or 20 mg/day) added to ongoing antihypertensive therapy (ACEI, ARB, and/or diuretic) significantly reduced blood pressure versus placebo (placebo-subtracted least squares mean reduction range: DBP -3.3 to -4.6 mmHg, p \ 0.001 all; SBP -3.7 to -6.2 mmHg, p B 0.015 all) and resulted in significantly more responders (range: 53.0-65.1 vs 41.3 %; p B 0.028 all) [59] .
In a 6-week double-blind, placebo-controlled trial in patients with stage 2 hypertension [60] , the effect of a nebivolol/lisinopril (5-20 and 10-40 mg/day, respectively) combination on baseline-to-endpoint change in DBP (primary efficacy parameter) was significantly greater than those of placebo (p \ 0.001), nebivolol alone (5-20 mg/day, p = 0.001), and lisinopril alone (10-40 mg/day, p \ 0.001). The change from baseline in SBP with the nebivolol/lisinopril combination was also significantly reduced compared with placebo (p \ 0.001) and nebivolol (p \ 0.05), but not versus lisinopril monotherapy [60] . A separate 12-week trial [61] investigated nebivolol (5-40 mg/day) as add-on therapy to lisinopril (10-20 mg/day) or losartan (50-100 mg/day) in patients with untreated or uncontrolled hypertension treated with lisinopril or losartan. Nebivolol as add-on therapy significantly reduced mean DBP versus placebo (-7.8 vs -3.5 mmHg; p \ 0.001), while the effects on SBP did not reach significance (-10.1 vs -7.3 mmHg). The authors suggested that a relatively strong placebo effect in this trial may limit data interpretation [61] .
Finally, an 8-week double-blind trial compared a singlepill combination (SPC) of nebivolol and valsartan (10/160, 10/320, and 20/320 mg/day) in patients with stage 1 or stage 2 hypertension [62] with nebivolol (10 or 40 mg/day), valsartan (160 or 320 mg/day), and placebo. All comparisons for change in DBP and SBP were significant in favor of the SPCs versus their monotherapy components [62] .
Nebivolol for the Treatment of Heart Failure (HF)
According to the 2013 American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) guidelines, the current standard treatment for HF is a combination of a RAAS inhibitor (an ACEI or an ARB) and a b-blocker [63] . b-blockers may improve the condition of patients with HF by reducing the myocardial workload (via lower heart rate) and by decreasing sudden death through reduction of arrhythmias [64] . The three b-blockers currently recommended by the ACCF/AHA guidelines-bisoprolol, carvedilol, and metoprolol succinate-were chosen based on observed reductions in mortality in multiple large-scale clinical studies [65] [66] [67] .
Patients with fluid retention can also be given a loop diuretic. In the case of patients who have left ventricular ejection fraction (LVEF) of B35 %, an aldosterone antagonist should be considered [63] . Elevated adrenergic activity in the heart muscle after injury causes a progressive degeneration that leads to left ventricular dysfunction and reduced LVEF. It follows that an adrenergic blockade would slow this degeneration and increase survival [65] , and numerous studies have shown that treatment regimens that include a b-blocker can reduce HF-related mortality [66] [67] [68] . A recent meta-analysis on bblocker use in HF patients with reduced ejection fraction (HFrEF) showed that b-blocker treatment confers a significant mortality reduction compared with placebo or active comparator (odds ratio [95 % confidence interval (CI)]: 0.71 [0.64-0.80]; p \ 0.001) [68] . Improvements up to 4 % were observed in LVEF, as well as reductions in sudden deaths and deaths from cardiovascular disease; these benefits occurred regardless of the treatment duration or b-blocker type [68] . However, the mechanisms of action through which b-blockers confer benefits in HF may not be limited to b-adrenergic blockade. The vasodilatory agents (nebivolol, carvedilol, labetalol) can reverse hypertensionrelated arterial remodeling [1, 2, 69] and arterial stiffness, both strongly associated with HF [70] . The exact role of those mechanisms, such as NO-mediated vasodilation in case of nebivolol [1, 69] , would have to be examined in dedicated trials [64] .
Nebivolol Studies in HF
Although nebivolol is currently not approved by the US Food and Drug Administration (FDA) for HF treatment, numerous studies suggest that it may be effective in treating patients with HF (Table 2 ). For example, in a randomized, double-blind study conducted in patients with uncomplicated hypertension, nebivolol (5 mg/day) preserved cardiac output while decreasing peripheral resistance [71] . Additionally, several studies conducted in patients with hypertension have shown that the hemodynamic effects of nebivolol are similar to or more favorable than those associated with the three ACCF/AHA-recommended bblockers [70] [71] [72] . While these studies included individuals with hypertension but without HF, the observed hemodynamic effects indicate that nebivolol may have favorable effects in HF. Furthermore, results from a small-scale HF study indicate that, in patients with HFrEF, nebivolol significantly lowers heart rate and SBP and improves stroke volume [72] . Results from another study suggest that nebivolol may be beneficial over metoprolol tartrate as it does not invoke the same negative hemodynamics seen with initiation of metoprolol tartrate [increased pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP) and decreased cardiac output (CI)] [73] . In a 12-month, randomized trial (N = 26) in patients with HF and preserved LVEF (HFpEF), hemodynamic improvements and exercise tolerance with nebivolol were greater than those observed with atenolol [74] . Finally, in the CARNEBI (Multiparametric comparison of CARvedilol, vs NEbivolol, vs BIsoprolol in moderate heart failure) cardiopulmonary trial, 70 patients with moderate HF who were given carvedilol, nebivolol, and bisoprolol for 2 months each showed improvements on measures of lung diffusion (p B 0.001) and exercise performance (p \ 0.0001) with nebivolol and bisoprolol [75] .
HF and Reduced Ejection Fraction (HFrEF)/Systolic HF
Several studies in patients with HF suggest that nebivolol treatment may be beneficial due to the decrease in heart rate compared with placebo and a possible improvement in EF, New York Heart Association (NYHA) classification, and symptoms [72, [76] [77] [78] . Two of these studies describe an effect on LVEF similar to that of carvedilol [77, 78] . [79] . However, the benefits of nebivolol in HF may be restricted to patients with HFrEF (EF \ 45 %), as a 6-month, randomized (1:1) trial in patients with HFpEF (mean age 66 years; N = 116) failed to show a difference in exercise capacity between nebivolol-and placebo-treated patients [80] . While current data suggest a benefit in elderly patients with HFrEF, most of whom had a history of coronary heart disease, more largescale, head-to-head, clinical outcome trials with bisoprolol, metoprolol succinate, and carvedilol are needed.
HF and Preserved Left Ventricular Ejection Fraction
(HFpEF)/Diastolic HF A benefit of nebivolol treatment in HFpEF is less clear than it is in patients with HFrEF. In addition to the study mentioned above, a study in which nebivolol treatment (titrated from 2.5 to 10 mg) over a 5 week period in patients with HFpEF resulted in no improvement in 6-min walk tests, peak oxygen consumption, NYHA classification, or Minnesota Living with HF questionnaire, versus placebo [80] . In contrast, two small-scale studies demonstrated a preferential hemodynamic effect with nebivolol vs atenolol and metoprolol, but clinical outcomes were not evaluated [74, 81] . At this time, the benefit of nebivolol use in patients with HFpEF is unproven and requires larger, randomized, clinical outcome trials.
Nebivolol and Erectile Dysfunction
The NO-mediated vasodilatory properties of nebivolol are possibly related to its benefits observed in erectile dysfunction (ED) over other b-blockers, which at worst have been associated with ED and at best have a neutral effect [90] . In a study of 44 men with hypertension treated with atenolol, metoprolol, or bisoprolol for over 6 months, switching to nebivolol treatment for 3 months resulted in an improvement in 20 out of 29 (69 %) patients who had ED, 11 of whom experienced a normalization of their erectile function [91] . In a randomized, 12-week, crossover trial of nebivolol and metoprolol in male outpatients with hypertension and no prior history of ED (N = 48), metoprolol was associated with a decrease in mean erectile function subscores on the international index of erectile function scale (p \ 0.05), while nebivolol had no effect [92] . In another 12-week trial of 131 hypertensive men randomized (1:1:1) to receive nebivolol, atenolol, or atenolol and the diuretic chlorthalidone, the mean number of satisfactory sexual intercourses per month declined by 47 and 56 % in groups treated with atenolol and atenololchlorthalidone, respectively (p \ 0.01, both), while it remained constant in the group treated with nebivolol [93] . Finally, a large cross-sectional observational study of men with high-risk hypertension receiving b-blocker therapy revealed that nebivolol was associated with a lower prevalence of ED compared with other agents, but this association was limited to younger patients [94, 95] .
Pharmacoeconomics of Nebivolol Use
Nebivolol is not yet available as a generic formulation in the US, which raises the question of its cost effectiveness compared with other b-blockers. There are no prospective studies that addressed this issue, but a retrospective claims analysis suggests that switching from C6-month treatment with generic metoprolol to C6-month treatment with nebivolol, although associated with a greater cost of treatment (US$52 per month in 2011 dollars), is also associated with a 33 % reduction in allcause hospitalizations, 60 % reduction in hospitalizations due to cardiovascular causes, 7 % reduction in monthly outpatient visits, and US$111 monthly reduction in inpatient costs (all differences: p \ 0.01), leading to overall cost neutrality [96] .
Limitations
The largest limitation in interpreting nebivolol trial data comes from an absence of outcomes trials in patients with hypertension, which limits our ability to assess the effect of nebivolol treatment on cardiovascular morbidity and mortality with any precision. Additionally, in the trial conducted in elderly patients with HF [79] in which a significant reduction of all-cause mortality and cardiovascular hospitalizations was observed with nebivolol versus placebo, the minimum follow-up period of 6 months was extended to 12 months by the Steering Committee due to an unexpectedly low rate of the combined primary event, observed in a blinded analysis [79] . This extension of the observation window was interpreted by the advisory panel of the US FDA as a potential source of bias [97] . An additional limitation is that there are currently few head-to-head trials comparing nebivolol with the core b-blockers used to treat HF. Consequently, nebivolol was not granted US approval for treatment of chronic HF, despite the fact that it is used for that purpose in numerous other countries.
Conclusion
Nebivolol is a third-generation, long-acting and highly selective b 1 adrenoreceptor antagonist that also exhibits NO-mediated vasodilatory effects. It is currently FDA-approved for treatment of hypertension. While b-blockers are not recommended as first-line therapy for treatment of essential hypertension, nebivolol has shown comparable efficacy to ACEIs, ARBs, and CCBs in lowering SBP and DBP in adults with mild to moderate hypertension. However, b-blockers as a class have been associated with cardiovascular outcomes that are similar to or worse than currently recommended therapies. Due to its unique mechanism of action, nebivolol offers some central hemodynamic effects that differ from non-vasodilating b-blockers. Therefore, extrapolation of results from previous b-blocker trials may not be appropriate with regard to nebivolol, and large clinical outcome trials are needed to validate any difference in clinical outcomes. While nebivolol does not currently carry an FDA approval for treatment of HF, current studies suggest that there may be clinical benefit for use in patients with HFrEF. Large comparison trials versus currently approved b-blockers are warranted. Alternatively, as with other b-blockers, data do not adequately support the routine use of nebivolol in patients with HFpEF. Nebivolol may be an appropriate alternative in patients who experience erectile dysfunction while on other b-blockers. Current research suggests that nebivolol may be a desirable treatment for specific indications, but further clinical investigation to determine its effects on cardiovascular morbidity and mortality is warranted.
